You are here: Industry Insights > metastatic melanoma

News List

Genetically modified viral injection could treat metastatic melanoma europeanpharmaceuticalreview
January 29, 2019
A study has reported that almost 40 percent of patients with non-surgically treatable tumours were effectively treated using a genetically modified virus…
FDA approval for Novartis' melanoma combo pharmatimes
July 12, 2018
The FDA has approved Novartis' Tafinlar(dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of BRAF V600E or V600K mutation-positive melanoma, as detected by an FDA-approved test, and involvement of lymph nodes, following comp
FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Un drugs.com
July 26, 2017
Bristol-Myers Squibb Company (NYSE:BMY) announced that FDA has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and olde
OncoSec and Merck to Evaluate Combination of ImmunoPulse IL-12 and Keytruda for Metastatic Melanoma americanpharmaceuticalreview
May 11, 2017
OncoSec Medical entered a clinical trial collaboration and supply agreement with Merck to evaluate the combination of OncoSec's ImmuoPulse IL-12 with Merck's anti-PD-1 therapy Keytruda (pembrolizumab) in a Phase II clinical trial, referred to as PISCES.